Detailed price information for Opus Genetics Inc (IRD-Q) from The Globe and Mail including charting and trades.

Good morning, and welcome to Ocugen First Quarter 2026 Financial Results and Business Update. [Operator Instructions] I will now turn the call over to Tiffany Hamilton, Ocugen's Head of Corporate ...

Six-month data from adult Cohort 4 show structural and functional improvements and a favorable safety profile; early safety data from pediatric ...

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, announced the completion of the adult dose escalation portion of the STELLAR phase 1/2 clinical trial ...

Conference Call and Webcast Today at 8:30 a.m. ETPositive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) ...

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the completion of the adult dose escalation portion of the STELLAR Phase 1/2 clinical ...

Ocugen Inc. (NASDAQ:OCGN) is one of the best biotech penny stocks to buy in 2026. On April 1, Ocugen completed dosing ahead ...

Background The standard of care for neovascular age-related macular degeneration (nAMD) is repeated intravitreal injection ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ...

Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage biotechnology company with a mission ...

An investigative team evaluated the real-world performance of faricimab in managing patients with AMD and subretinal ...

Roughly 200 million people worldwide live with age-related macular degeneration, a condition that erodes central vision and, ...